Advertisement

Topics

Transition to Rebif New Formulation

2014-08-27 03:32:50 | BioPortfolio

Summary

To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurance of flu-like symptoms.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Conditions

Relapsing Multiple Sclerosis

Intervention

Rebif New Formulation + prophylactically Ibuprofen, Rebif New Formulation + ibuprofen PRN

Location

Local Medical Information
Paris
France

Status

Completed

Source

EMD Serono

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:32:50-0400

Clinical Trials [1519 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of...

REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

The primary objective of the study is to evaluate the effect of Rebif New Formulation 44 mcg (tiw and ow) versus placebo on the time to conversion to McDonald MS in patients with a first c...

Study Comparing the Efficacy ofTwo Ibuprofen Formulations

This is a study of healthy volunteers to compare how quickly different ibuprofen products relieve dental pain.

Study Evaluating a Novel Ibuprofen Formulation in the Treatment of Dental Pain

This study will compare the analgesic efficacy of a single-dose of a novel ibuprofen formulation to placebo and two formulations of standard ibuprofen in the treatment of post-surgical den...

Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis

This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-...

PubMed Articles [1159 Associated PubMed Articles listed on BioPortfolio]

Ibuprofen plus paracetamol versus ibuprofen in acute low back pain: a randomized open label multicenter clinical study.

to estimate whether combination of ibuprofen and paracetamol is more effective than ibuprofen in monotherapy, in the treatment of acute low back pain.

Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.

The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart® electronic device provides useful information about adherence to the treat...

IMPROVED EFFICIENCY OF IBUPROFEN BY CATIONIC CARBOSILANE DENDRITIC CONJUGATES.

IIn order to improve the efficiency of the anti-inflammatory drug ibuprofen, cationic carbosilane dendrimers and dendrons with ibuprofen at their periphery or at their focal point, respectively, have ...

PEG-Fmoc-Ibuprofen Conjugate as a Dual Functional Nanomicellar Carrier for Paclitaxel.

Ibuprofen is a kind of non-steroidal anti-inflammatory drugs (NSAIDs), and considered to possess some antitumor effect. In this study, a novel nanomicellar carrier based on PEG-derivatized ibuprofen, ...

Ibuprofen results in alterations of human fetal testis development.

Among pregnant women ibuprofen is one of the most frequently used pharmaceutical compounds with up to 28% reporting use. Regardless of this, it remains unknown whether ibuprofen could act as an endocr...

Medical and Biotech [MESH] Definitions

A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.

Disorders in which phagocytic cells cannot kill ingested bacteria; characterized by frequent recurring infection with formulation of granulomas.

A field of biological research combining engineering in the formulation, design, and building (synthesis) of novel biological structures, functions, and systems.

More From BioPortfolio on "Transition to Rebif New Formulation"

Quick Search
Advertisement
 

Relevant Topic

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...


Searches Linking to this Trial